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lack of a small animal model. GB virus B (GBV-B), which infects new world monkeys, has been proposed as a surrogate
system for HCV replication. Despite their short genetic distance, however, diﬃculties exist when extrapolating results
from GBV-B to the HCV system. One way of addressing this is the creation of chimeric GBV-B containing HCV
elements.
Methods:Construction and analysis of GBV-B chimeras in which the p13 ion channel was replaced by its HCV coun-
terpart, p7.
Results:Replacing all, or part of, the GBV-B p13 protein with HCV p7 resulted in viable chimeras which replicated at
wild-type levels in marmosets following intra-hepatic RNA injection. Serum from one animal injected with chimeric RNA
was infectious in three naı¨ve recipients, indicating that chimeras formed fully infectious virions. Amantadine, which blocks
the ion channel activity of both HCV and GBV-B proteins in vitro, also inhibited GBV-B replication in primary
hepatocytes.
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Hepatitis C virus (HCV) is estimated to infect over
170 million individuals causing severe liver disease.
Therapy comprising pegylated interferon-a and ribavi-
rin is eﬀective in only 50% of cases [1], due to drug resis-
tance [2]. New anti-virals have been delayed by a lack of
convenient small animal models, attributable to HCV’s
restricted tropism for humans and chimpanzees (Pan
troglodytes). Chimpanzees are endangered and present
ethical dilemmas to researchers. Recently developed
mosaic murine/human liver models are technically chal-
lenging and lack host responses to infection [3,4].
GB virus B (GBV-B) is the closest relation to HCV
[5,6]; sharing 28% amino acid identity overall. It is a hep-Published by Elsevier B.V. All rights reserved.
Fig. 1. The E2–p13–NS2 region of GBV-B. p13 (614–732, GBV-B
sequence) deletion mutants and insertion of HCV sequences are
indicated. The N-terminal domain (614–681) in black and C-terminal
domain (681–732) in white were deﬁned according to predictions
described by Ghibaudo et al. [27], HCV p7 from the J4 isolate
(746–809, HCV sequence) in grey was inserted in place of either the
C-terminal domain or the entire p13 region using fusion PCR.
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belong within the Hepacivirus genus alongside HCV.
GBV-B primarily causes an acute, resolving hepatitis in
both tamarins (Saguinus sp.) and common marmosets
(Callithrix jacchus) [7–9]. Infectious sera can be passaged
in primary hepatocytes from these species [10]. GBV-B
has been proposed as an HCV pathogenesis model and
has been used to characterise anti-virals [11,12]. Despite
their short genetic distance, however, diﬀerences exist
between GBV-B and HCV [11] which could be addressed
by the generation of chimeras, as in other Flaviviridae
[13,14]. Viable GBV-B/HCV 50 UTR chimeras have been
reported, validating this approach [15].
HCV p7 presents an attractive anti-viral target. We
demonstrated its function as an amantadine-sensitive
ion channel [16–18] and others have subsequently identi-
ﬁed alternative inhibitors [19,20]. p7 comprises two trans-
membrane alpha helices linked by a basic loop required
for both function in mammalian cells [17] and replication
in chimpanzees [21]. p7 localises to ER membranes [22–
24] and also post-Golgi compartments [17], consistent
with a recently deﬁned role in HCV assembly [25,26].
The GBV-B p7 homologue contains four trans-mem-
brane domains and is designated p13 [27]. In vitro anal-
ysis highlighted a second processing event between
amino acids 681/682 (Fig. 1) [27] and recent in vivo stud-
ies have mapped this cleavage to residues 669/670; sep-
arating p13 into an N-terminal p6 and a C-terminal
‘‘p7”, the latter being required for replication in tama-
rins [28]. GBV-B p7 also acts as an amantadine-sensitive
ion channel in vitro [29], conﬁrming it as the functional
equivalent of HCV p7.
Here, we describe viable chimeric GBV-B where all or
part of p13 has been replaced by HCV p7, representing
the ﬁrst example of GBV-B/HCV coding sequence chi-
meras. Development of these chimeric viruses could lead
to a future small animal model for p7 inhibitors.2. Materials and methods
2.1. GBV-B/HCV DNA constructs
GBV-B (pGBB) and genotype 1b J4 HCV (pCVJ46LS) infectious
clones have been described [30,31]. Deletions and chimeras were gener-
ated by overlap/fusion PCR using Pfu polymerase (Stratagene) (primer
sequences and detailed methodology available upon request). Clones
were veriﬁed by dsDNA sequencing. RNA was prepared using the T7
Megascript kit (Ambion) anddiluted in PBS to 1 lg/ll prior to injection.
p13/p7 expression constructs were generated by PCR using wild-
type or mutated sub-clones as templates (primer sequences available
upon request). Amplimers (coding for amino acids S573 to S780) were
cloned into pCDNA3.1 (Invitrogen) and veriﬁed by dsDNA sequenc-
ing. pCDNA-SPp7 has been described [23].2.2. Human cell culture and transfection
Human embryonic kidney (HEK) 293T cells were passaged and
transfected as described [23].2.3. Virus infection and inhibition assays
Primary hepatocytes were isolated from euthanised marmosets
using the standard two step collagenase procedure [10]. Hepatocytes
were infected for 2 h with GBV-B infectious serum diluted in serum-
free media (8  107 genome copies in 0.5 ml) ± inhibitors (4 lM), then
washed 3 times prior to addition of serum-free media containing drugs.
Cultures were incubated for 7 days with media replaced every 2–3 days.
Supernatants were stored at 20 C for analysis. For ﬂuorescence
studies, infected cells were washed 3 times with PBS and ﬁxed with
4% paraformaldehyde.
Vero cells in a 60 mm Petri dish were infected with 80–100 p.f.u.
yellow fever virus (YFV, 17D strain) and cultured ± inhibitors
(20 lM) for 6 days in a standard plaque reduction assay. Compound
cytotoxicity was assessed by MTT assay in exponentially growing Vero
cells over a four day period.
2.4. Antibodies, immunoﬂuorescence and Western blot
analysis
Immunoﬂuorescence and western blots were carried out as
described [23]. Antibody 1055 has been described [23]. Rabbit antibody
1795 was raised against peptide YPLRPVLPSQSYLQ (GBV-B amino
acids 614-627), aﬃnity-puriﬁed and used at a concentration of 1 lg/ml.
Rabbit anti-GBV-B core antibody has been described [32,33].
910 S. Griﬃn et al. / Journal of Hepatology 49 (2008) 908–9152.5. Hepatic RNA injection and infection of marmosets
Marmosets (C. jacchus) were bred and housed at GSK. Animal use
was in accordance with UK Animals (Scientiﬁc Procedures) Act 1986
and approved by internal ethical review. Animals were housed in pairs
with appropriate environmental enrichment. Juvenile males and
females (average 350 g) were anaesthetised with isoﬂurane, an incision
made in the abdomen and the right lobe of the liver visualised. 150 lg
of RNA (2  100 ll aliquots) was injected slowly into the liver at two
separate sites; injections judged successful by liver blanching. Incisions
were closed with internal sutures and external sub-cuticular sutures
prevented wound re-opening. Appropriate analgesia was provided
for 24 to 48 h post-operatively.
Marmosets were infected intravenously in the right femoral vein
with 0.5 ml of GBV-B(DC + p7) or wild-type infectious sera
(3.5  104 or 5  105 genome copies per animal, respectively). Weekly
blood samples (0.5 ml) were taken from either the left or right femoral
vein. Sera were stored at 20 C.
2.6. Quantitative Analysis of GBV-B RNA
RNA was extracted from serum (50 ll), cells (106) or culture
supernatant (140 ll) using QIAamp viral RNA mini spin columns
(Qiagen), stored at 80 C and quantiﬁed using real-time PCR
(Taqman) using a core-speciﬁc primer/probe combination (avail-
able on request). Standard reactions were performed in triplicate
using the EZ-RT PCR kit (Applied Biosystems) (conditions and pri-
mer sequences available on request). Quantiﬁcation was achieved by
standard curve using serial tenfold dilutions of in vitro transcribed
core region RNA (from 108 to 101 copies/ll). For low level RNA
detection, standard protocols were enhanced by performing eight
replicates on at least two separate occasions to rule out false-
positives.
2.7. Sequence analysis of chimeric GBV-B RNA
RNA was puriﬁed from marmoset AA383 liver homogenate or
from animals injected with GBV-B(DNC + p7) RNA (ﬁve pooled
serum samples, 750 ll, average titre 6.4  103 genome equivalents/
ml) or GBV-B(DC + p7) RNA (two pooled serum samples, 300 ll,
average titre 4.8  104 genome equivalents/ml) using the Qiagen Ultra-
sensitive RNeasy kit, yielding 50 ll RNA.
cDNA was generated by Superscript III (Invitrogen) using a
gene-speciﬁc RT primer and 5 ll RNA. A positive control of 7.5
or 0.75 fg GBV-B(DNC + p7) in vitro transcribed RNA was
included. Two rounds of PCR were performed using High Fidelity
PCR mastermix (Roche) with 5 ll template (conditions and primer
sequences available on request). Products were sequenced with
GBV-B-speciﬁc primers using an ABI 377 sequencer (Applied
Biosystems).3. Results
3.1. Generation of chimeric GBV-B containing HCV p7
A series of viruses was constructed where all or part
of p13 had been deleted or replaced by HCV genotype
1b p7 (Fig. 1). At the time, processing at 669/670 had
not been described [28], so the HCV cassette replaced
amino acids 614–732 (N & C-terminal region) or 682–
732 (C-terminal region only) of the GBV-B sequence
based on earlier studies [27], generating GBV-
B(DNC + p7) and GBV-B(DC + p7), respectively. In
addition, p13 (DNC) and amino acids 614–682 (DN) del-
etants were generated.3.2. Characterisation of chimeric p13/p7 in cell culture
Signal peptidase processing of GBV-B p13 has been
demonstrated in both reticulocyte lysate and transient
transfection systems [27,28]. Similarly to HCV p7 [34–
37], processing in this region is delayed, resulting in
the presence of precursors. In addition, internal process-
ing of p13 has recently been shown to occur at position
669/670 in vivo [28] requiring conﬁrmation of appropri-
ate processing for chimeric proteins.
We investigated sub-cellular localisation and pro-
cessing of chimeric p13/HCV p7 in mammalian cells
using HCV p7-speciﬁc (1055) and GBV-B p13-speciﬁc
(1795) antibodies. Plasmids encoding wild-type or chi-
meric sequences were generated (S573–S780), encom-
passing the predicted signal sequence from E2, p13
and the ﬁrst trans-membrane domain of NS2 (V582-
A766).
Immunoﬂuorescence of HEK 293T cells expressing
HCV p7, wild-type p13 or chimeric constructs revealed
an ER-like staining pattern in all cases that signiﬁcantly
overlapped with Concanavalin A, an ER/Golgi marker
(Fig. 2A). Western blots using 1055 detected p7 in the
HCV positive control as well as in both chimeric con-
structs; albeit to lower levels (Fig. 2B). 1795 was not
reactive in western blots. For the DNC + p7 chimera,
a single reactive species co-migrated with the positive
control, indicating eﬃcient processing at the junction
of the GBV-B and HCV sequence. In the case of the
DC + p7 chimera, however, two species of 7 and
13 kDa were evident, implying partial processing rem-
iniscent of wild-type p13.
3.3. GBV-B p13/HCV p7 chimeric RNAs establish
productive infection in marmosets
To determine viability, naı¨ve animals were injected
with chimeric or wild-type RNA and virus replication
followed for 10 weeks via serum RNA levels.
Three animals injected with wild-type RNA were
PCR-positive for between three and ten weeks post-injec-
tion, although detection of RNA occurred sporadically
and was of relatively low titre, 105 genome equiva-
lents/ml (Fig. 3A). Such sporadic replication is observed
where marmosets are infected with tamarin virus [11];
pGBB being a tamarin-derived GBV-B sequence [30].
Pairs of marmosets were injected with chimeric
RNAs containing HCV p7, or deletion mutants. GBV-
B(DNC) and GBV-B(DN) were non-viable (data not
shown), conﬁrming p13 is necessary for GBV-B replica-
tion in marmosets and consistent with cleavage occur-
ring between 669/670, not 681/682 [27,28]. These
animals were PCR-negative at all time points, and pro-
vided baseline controls for further experiments.
DNC + p7 and DC + p7 chimeric RNAs established
infection following injection and serum RNA reached
Fig. 2. Analysis of wild-type and chimeric p13/p7 proteins in culture.
Expression constructs for wild-type or chimeric p13/p7 proteins were
transfected into HEK 293T cells and their intra-cellular localisation and
processing by cellular signalases analysed. (A) Top panels – Detection of
wild-type p13 and DC + p7 protein using 1795 (Alexa-ﬂuor 488 nm
secondary). Left column shows p13-speciﬁc ﬂuorescence (green channel),
middle column shows Alexa-ﬂuor 594 nm-conjugated Concanavalin A, a
marker for ER/Golgi membranes (red channel), and right column shows
an over-lay incorporating Hoechst staining of nuclei (blue channel).
Bottom panels – Detection of chimeric p13/p7 proteins using 1055
(Alexa-ﬂuor 488 nm secondary) (left column), other columns as above.
(B) Detection of chimeric proteins via Western-blot (WB) using anti-p7
antibody, 1055, using 106 HEK 293T cells/lane lysed in 200 ll Laemmli
buﬀer. Bands migrating at 7 kDa were identiﬁed using lysates containing
HCV p7 as controls (black arrow). A higher molecular weight species
corresponding to unprocessed DC + p7 chimeric protein was also evident
(grey arrow). (For interpretation of color mentioned in this ﬁgure the
reader is referred to the web version of the article.)
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pattern, although higher serum titres seemed to cluster
at early time points for the chimeras and were reduced
at later time points in comparison to wild-type virus.
This may indicate that these infections were more rap-
idly resolved, though direct comparisons using small
numbers of animals are diﬃcult. One animal injected
with DNC + p7 RNA (AA383) was sacriﬁced after three
weeks due to acute illness. Post-mortem examination
revealed hepatomegaly, and histology indicated severe
hepatitis (data not shown); bacterial infection was ruled
out, implying that the hepatitis was virus-mediated.
3.4. Chimeric virus sequences are stably maintained
Given that insertion of foreign genetic material into
the GBV-B genome can cause genetic instability [38], it
was important to conﬁrm that viruses establishing pro-
ductive infection maintained the chimeric sequence.
Nested RT-PCR ampliﬁcation of the p13 region was
performed on RNA extracted from excised liver tissue
of animal AA383 and wild-type GBV-B infected tama-
rin serum as a positive control. Reassuringly, the amp-
limer obtained from AA383 was smaller (505 bp) than
wild-type (670 bp), as expected from the DNC + p7 chi-
mera (Fig. 3D). Sequence analysis of the amplimer con-
ﬁrmed the presence of the HCV p7 cassette with no
mutations or deletions (data not shown). Pooled sera
from AA383 and AA295 gave an identical PCR amplim-
er which was also veriﬁed by sequencing (data not
shown) and co-migrated with positive controls
(Fig. 3D, right hand panels). Nested RT-PCR from
DC + p7 animals did not yield suﬃcient product for
sequencing.
3.5. Serum from chimeric RNA-injected marmosets is
infectious
To verify that the chimeric viruses generated infec-
tious virions, serum taken from one DC + p7 animal
(P164) at peak viraemia (Fig. 3C) was injected intrave-
nously into three naı¨ve animals. All animals became
infected, albeit to low levels, exhibiting sporadic peaks
of virus RNA in serum (Fig. 4). This low level of rep-
lication may reﬂect the low titre of virus inoculum,
which was less than a 50% marmoset infectious dose
(MID50) (10
6 genome copies for wild-type tamarin-
derived virus). Infection with a lower titre inoculum
results either in no replication, or in sporadic replica-
tion as observed here [11]. Nevertheless, the fact that
chimeric RNA was reproducibly detectable in serum
up to 9 weeks post-injection showed that the virus
was able to establish a low-grade infection in these
animals.
Fig. 3. Replication of wild-type GBV-B and chimeric viruses in marmosets following intra-hepatic RNA injection. Marmosets received a total of 150 lg
of either wild-type or chimeric RNAs via intra-hepatic injection. GBV-B RNA from serum was measured using quantitative RT-PCR (Taqman). (A)
Titres following injection with wild-type GBV-B RNA. (B) Titres following injection with DNC + p7 chimeric RNA, indicates where animal AA383 was
sacriﬁced due to acute illness. (C) Titres following injection with DC + p7 RNA, #indicates where serum taken from animal P164 for infection of naı¨ve
animals. (D) Nested RT-PCR for p13 region on RNA extracted from animal AA383 liver homogenate (left panel) or from pooled sera of the two injected
animals (right panel). A positive (+ve) control using either 7.5 or 0.75 fg of in vitro transcribed chimeric RNA as template is shown for comparison.
Fig. 4. Chimeric GBV-B/HCVp7 is transmissible to naı¨ve marmosets.
Three naı¨ve marmosets were injected intra-femorally with serum from
animal P164 containing 3.5  104 copies DC + p7 RNA. Serum titres
were monitored via Taqman RT-PCR for GBV-B RNA for 11 weeks.
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primary marmoset hepatocytes
Resources prevented testing potential p7 inhibitors in
live animals. As GBV-B readily infects primary hepato-
cytes [10], we utilised this system to demonstrate
whether virus spread could be blocked by amantadine,
which has been shown to inhibit the activity of both
the C-terminal domain of p13 and HCV p7
in vitro[16–18,29]. To demonstrate productive infectionwith GBV-B, cells infected in parallel were analysed
for both p13 and core protein by immunoﬂuorescence
(Fig. 5A). p13 staining displayed a punctate localisation
in these cells, reminiscent of N-terminally tagged HCV
p7 [23]. Core protein also showed punctate staining,
likely due to lipid droplet association [32,33].
Others have found amantadine not to aﬀect the
spread of GBV-B in primary cell culture [29], so to
ensure speciﬁcity we also tested three amantadine-like
compounds previously shown to block the activity of
HCV p7 in vitro; termed GSK 1–3 [39]. Compounds
were also tested at a ﬁvefold higher concentration
against the related Flavivirus, YFV, which utilises simi-
lar cellular pathways to HCV/GBV-B during virus
assembly, yet importantly does not encode a viroporin.
In each case, virus replication was monitored by super-
natant RNA levels using Taqman. MTT assays were
also performed for each compound to determine the cell
culture 50% inhibitory dose (CCID50).
Amantadine present throughout infection at 4 lM
reduced GBV-B RNA levels by 84% compared with
untreated controls, yet displayed no appreciable activity
against YFV at ﬁve times this concentration (Fig. 5B).
This could not have been due to cytotoxic eﬀects as
for GBV-B the drug was used at around 2% of the
CCID50. GSK 1 and 3 were ruled out as having virus-
Fig. 5. Analysis of GBV-B p13 in cultured primary marmoset hepato-
cytes. (A) Freshly explanted primary marmoset hepatocytes were
infected with GBV-B at 8  107 genome copies/ml in serum-free media.
After 7 days cells were ﬁxed and stained for either p13 or core protein as
described in materials and methods and visualized by Confocal micros-
copy. (B) Replicate GBV-B infections were performed as above but in the
presence of amantadine (4 lM), GSK inhibitors 1–3, or DMSO control.
GBV-B RNA in the supernatant was measured using quantitative RT-
PCR (Taqman) seven days post-infection. Inhibitors at ﬁvefold concen-
tration were also tested for eﬀects on YFV and the cell culture 50%
inhibitory dose was also determined by MTT assay. Results in virus
systems are expressed as % inhibition to allow direct comparison. (For
interpretation of color mentioned in this ﬁgure the reader is referred to
the web version of the article.)
S. Griﬃn et al. / Journal of Hepatology 49 (2008) 908–915 913speciﬁc eﬀects due to their low CCID50, whereas the
GSK-2 compound was almost as potent as amantadine
against GBV-B. These data demonstrate that, like HCV,
GBV-B is dependent on p7 activity for eﬃcient produc-
tion of infectious virus and suggest that an optimised
chimeric virus system may be a suitable model for the
testing of p7 inhibitors in vivo.4. Discussion
This study describes the ﬁrst viable Hepacivirus cod-
ing sequence chimeras. Despite recent advances in cell
culture systems for HCV [40–42], drug development
programmes would ideally include small animal systems
prior to clinical trials. Tailoring the GBV-B system to
include HCV proteins as described here, could expedite
the development of new HCV therapies.Levels of virus replication in this study were repro-
ducible and comparable for both wild-type and chimeric
RNAs. The RNA injection protocol, however, was
clearly less eﬃcient at establishing GBV-B infection
compared to studies in tamarins, or where marmosets
have been infected intravenously [8,9,30]. This may in
part be due to the fact that the pGBB clone was derived
from a tamarin. We previously noted that initial infec-
tion of marmosets with tamarin-derived virus results in
low level, sporadic infection; requiring subsequent pas-
sages to obtain high serum RNA levels [11]. This would
imply that adaptive mutations are responsible for such
changes, unfortunately further investigations were
beyond our previous remit and the amount of serum
we were able to obtain during this work prohibited full
genome sequencing. Nevertheless, we were able to show
that, both in liver and serum, the chimeric p13/p7
sequence was maintained in these animals. It is reason-
able to assume, therefore, that pGBB based chimeric
viruses would, upon repeated passage, also become bet-
ter adapted to the marmoset host.
Levels of chimeric virus replication in naı¨ve animals
receiving serum from injected subjects were low. We
are convinced, however, that this represented true virus
replication as one animal tested positive on three occa-
sions over an 11 week period and the other two were
positive four and nine weeks post-infection, respectively.
This is unlikely to represent PCR error as no such signal
was detectable in animals injected, so presumably receiv-
ing far greater amounts, with RNAs demonstrated to be
non-viable (GBVB(DNC) and GBV-B(DN)). Further-
more, in studies of GBV-B with unstable HCV genetic
insertions, viral RNA was undetectable by week three
post-injection suggesting that non-replicating RNA does
not persist for appreciable time periods [38]. Instead,
low level sporadic infection likely reﬂects the low infec-
tious dose; only 3.5  104 genome equivalents each; sev-
eral log10 lower than usually used in such studies and
below that which reliably gives infection of marmosets
using tamarin-derived virus; a single marmoset passage
being inadequate to adapt tamarin GBV-B for eﬃcient
infection [11]. Development of this system for future
drug development will obviously require more reliable
infections, which may be addressed by the use of tama-
rins in preference to marmosets.
Previous attempts to generate chimeric GBV-B con-
taining p7 from genotype 1a HCV (H77) in place of
p13 were non-viable in tamarins [28]. Why this virus
was non-viable when DNC + p7 replicated to wild-type
levels in marmosets is unclear, though this may be due
to the diﬀerent HCV amino acid sequences used in each
study. The same group has previously shown that inter-
genotypic p7 HCV were non-viable in chimpanzees
except where the p7 N and C termini were maintained
as the parental genotype [21]. Two possible explanations
for non-viable chimeric sequences, therefore, are a resul-
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speciﬁc interaction of the p7 termini with other viral
proteins. Changes in the p7 termini and ﬂanking
sequences have been shown to aﬀect signalase cleavage
[34,35], yet the chimeric proteins were processed simi-
larly to GBV-B p13 in a model 293T system and local-
ised to ER membranes (Fig. 2) as has been observed
for HCV p7 [22–24]. Evidence from the HCV culture
system implies that both p7 and NS2 undergo critical
protein–protein interactions during virus assembly
[25,26,43]. As the chimeras did not acquire mutations
in the p7/p13 region, it is possible that these interactions
are less important for GBV-B assembly, or that the 1b
p7 is able to interact appropriately with GBV-B pro-
teins. We cannot, however, rule out that compensatory
mutations have occurred elsewhere in the chimeric gen-
ome, as has been observed in the HCV culture system
[44]. Furthermore, it should be noted that this study
was carried out using marmosets, not tamarins, raising
the possibility that host cell factors might account for
the viability of the chimeric virus RNAs.
Although resources did not permit this study to
include anti-viral treatment in animals, the observation
that amantadine reduced yield of GBV-B in primary
hepatocyte culture implies that p7 inhibitors may be
eﬀective in vivo. This is contrary to the ﬁndings of other
investigators in primary culture [29], yet is consistent
with the in vitro eﬃcacy of the drug against GBV-B p7
reported in the same study. The reason for this contra-
diction is unclear, but it may relate to the higher initial
viral titres used in the current study highlighting a more
subtle eﬀect; the inhibitory eﬀect being moderate at
approximately tenfold. Interestingly, a recent report
has found amantadine to be ineﬀective at preventing
the spread of HCV intergenotypic chimeras in culture
[45]. Our observations show that amantadine, as well
as other p7 inhibitors identiﬁed from in vitro studies
[18–20,39], vary in eﬃcacy against chimeric HCVs in
culture according to genotype as well as sub-type [46]
and so may also be expected to vary in eﬃcacy against
GBV-B. Our observations are unlikely to be due to cyto-
toxic or oﬀ-target eﬀects based on MTT and YFV assay
data, implying that the reduction in GBV-B spread is
solely due to a block in p7 function, thereby reducing
secretion of infectious virus.
This work advances GBV-B as a model for HCV
infection by successfully exchanging coding sequences
between the two viruses, generating functional chimeras.
It also demonstrates that the HCV and GBV-B p7 pro-
teins are functionally equivalent in vivo and will poten-
tially enable future testing of p7 inhibitors in a small
animal model. Optimisation of this system by the use
of tamarins may allow the generation of alternative chi-
meras expressing other HCV proteins of therapeutic
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